Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: A 6-month open study

Journal of the Medical Association of Thailand

Volumn 87, Issue 11, 2004, Pages 1293-1300

  Suwantamee, Jithanorm ^a   Nidhinandana, Samart ^b   Srisuwananukorn, Suwat ^c   Laptikultham, Somsak ^d   Pisarnpong, Apichart ^e   Chankrachang, Siwaporn ^f   Bundhukul, Adul ^g  

^a Department of Neuro psychiatry   (Thailand)

^b PRAMONGKUTKLAO HOSPITAL   (Thailand)

^c NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^d RAJAVITHI HOSPITAL   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^g Noppraratratchathani Hospital   (Thailand)

Author keywords

Dopamine agonist; Non ergot; Parkinson's disease; Piribedil

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PIRIBEDIL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PARKINSON DISEASE; SCORING SYSTEM; TREATMENT OUTCOME; VERTIGO; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PIRIBEDIL;

EID: 13744253467     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Land AE, Lozano AM. Parkinson's disease. N Engl J Med 1998; 339: 1130-43.
2. th ed. New York: McGraw-Hill Company, 2001: 549-68.
3. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994; 44(Suppl 6): S15-8.
4. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology 2001; 56(Suppl 5): S1-88.
5. Olanow CW. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease. In: Dopamine Agonists in Early Parkinson's Disease. Olanow CW, Obeso JA (Editors), Wells Medical, Kent, UK, 1997: pp 37-52.
6. Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm 1995; 45(Suppl): 187-95.
7. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993; 329: 1021-7.
8. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin 2002; 18: 209-14.
9. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? (1998) Neurology 51(Suppl2): S21-4.
10. Maurin B, Baunez C, Bonhomme C, Chezaubernard C, Nieoullon A, Amalric M. Cognitive deficits in 6-OHDA lesioned rats are improved by chronic treatment with the dopamine agonist piribedil. Behav Pharmacol 2001; 12(Suppl 1): S63.
11. Schafer D, Greulich W. Effects of parkinsonian medication on sleep. J Neuro 2000; 247(Suppl 4): IV/24-IV/27.
12. 2- adrenoceptor antagonist properties: A multivariate comparison to other antiparkinsonian agents at recombinant, human monoaminergic receptors. Mov Disord 2002; 17(Suppl 5): S28.
13. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicenter study. Neurology 1992; 239(Suppl 1): S28-34.
14. Metenopoulous G, Katsarou Z, Bostantjopoulou S, Logothetis J. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form. Clin Neuropharmacol 1989; 12: 23-28.
15. Kwiecinski H, Fedorova N, Takats A, Ruzicka E, Jamrozik Z, Del Signore S. A multicenter trial of piribedil as early adjunct treatment for Parkinson's disease: Piribedil International Study Group (PISG). Neurology 2002; 58(Suppl 3): A163.
16. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to L-dopa in patients with stable Parkinson's Disease: a 6-month randomized placebo controlled study. Mov Disord 2003; 18/4: 418-25.
17. Shulman LM. How to succeed in using dopamine agonists in Parkinson's disease. Eur J Neurol 2000; 7(Suppl 1): 9-13.